Search Results for: temperature control
QPatch ll Temperature Control
Laboratory temperatures can change from winter to summer or during the day and affect the reproducibility and repeatability of your assay results. With QPatch II temperature control you can ensure that assays are always performed at a constant and controlled temperature (between 10-42°C) with high accuracy (+/-0.5°C).
Consider the temperature control add-on module if you want to:
- keep a constant controlled temperature to increase repeatability
- perform assays at physiological temperatures 35-37°C
- Log assay temperature for GLP and tracking purposes
The new QPatch ll temperature control and regulate temperature at the Bed-of-Nails directly beneath the measurement sites and also the manifold is thermostated to ensure rapid equilibration.
The recorded temperature data is transferred automatically to the analyzer software where further analysis can be made.
Click here to read more about design, accuracy, precision and validation work. Click here to visit the product page.
QPatch II – Temperature control
QPatch II temperature control is designed to allow for accurate and rapid control of temperature.
Temperature measurement and feedback are directly from bed-of-nails (BON) directly beneath measurement sites.
Temperature regulation is performed using circulating liquid in the BON. It was not an easy engineering task to integrate liquid flow in the BON, however vigorous testing have proven than temperature control needs to be perform close to the measurement sites to ensure a precise control with minimum fluctuations. Controlling e.g. cabinet temperature did not at all meet our requirements of +/- 0.5°C accuracy
Also, to increase equilibrium time also the manifold base plate is thermostated.
Data is registered and stored in Oracle database together with electrophysiology data.
|Across plate variation (range)||0.50°C|
|Fluctuation over time (range)||0.25°C|
|Machine to machine reproducibility (range)||<0.50°C|
Temperature control for QPatch IILaboratory temperatures can change from winter to summer or during the day. With the QPatch
Temperature control on Qube 384 – pharmacological dependency of hERG reference compounds
Studies of temperature dependencies can be done efficiently and reliably on Qube 384. In this study we directly measure change in potency with change in temperature on four different compounds, emphasizing the importance of temperature when studying drug candidates.
See the new application report here.
Temperature control on Qube 384 – pharmacological dependency of hERG reference compounds
To better understand how compounds function in warm-blooded animals such as humans, it is key to be able to test compound potency at physiological temperature. Our automated patch clamp systems provid
Temperature control for QPatchControlling the temperature of your experiment standardizes the testing environment and reduces outs
Temperature control for Qube 384Qube offers the ability to record high fidelity electrophysiological effects at varying temperatures
Estimating hERG drug binding using temperature-controlled high throughput automated patch clamp
The human ether-à-go-go related gene (hERG) carries one of the major repolarizing currents in the heart myocytes and block of this channel by certain drugs may lead to prolongation of the cardiac
Poster presented at SPS in Berlin in September on temperature effect using Qube
Until recently, the only possibility to test compound potency under voltage control conditions has been the manual patch clamp technique. Now automated patch clamp instruments with temperature control have become available making it possible to perform up to 384 parallel recordings at controlled temperatures ranging from 8°C and above. Qube has a temperature controlled test environment and in these studies, we show that temperature merits being taken into consideration when evaluating for hERG pharmacology. See the poster here.
Temperature effect on hERG channel pharmacology measured using the Qube automated patch clamp system
The human ether-à-go-go related gene (hERG) function is important for cardiac repolarization and inhibition of the channel can prolong the cardiac action potential, which gives increased risk for ven
Successful hERG recordings at 22°C and 35°C on QPatch II
When conducting your ion channel experiments a key environmental factor to consider is temperature. In this latest application report, the conductance, kinetics and pharmacology of the hERG ion channel current, a critical component of the cardiac action potential, were recorded at 22°C and 35°C.
Like nearly all physiological processes, the activity and pharmacology of ion channels are highly dependent on temperature. Whether making ion channel recordings at mammalian body temperature (~35°C) or simply a consistent room temperature (RT), it is imperative to accurately control the temperature of your recordings. Even ‘simply’ ensuring all your recordings are not subject to the particular vagaries of the lab’s diurnal/seasonal micro-climate can be challenging. With temperature control, by setting the recording site to RT means accurately recording and reporting at 22°C, not the 18-27°C that we all know can be the real world lab RT.
If you want to learn more about temperature control on Sophion’s platforms, read more here
QPatch ll 48 installed at ApconiX
ApconiX, the integrated toxicology and ion channel company, has acquired a QPatch ll 48 with temperature control to meet the increasing demand from their clients. As the first CRO to invest in QPatch II in the UK, this instrument allows the ApconiX team to continue to deliver top-quality ion channel services for their existing and new clients and to further deliver on their exceptional data quality and rapid turnaround time.
The QPatch ll system was selected for its unique possibility to achieve gigaohm seals in physiological solutions, without the use of seal enhancers and for its ability to control the temperature at the measurement sites. The instrument was installed at the beginning of November and the installation went smoothly. The ApconiX team were able to handle assay setup, execution of experiments and results analysis within the week of installation and training.
Director and Co-founder of ApconiX, Michael Morton, explains:
“We know Sophion Bioscience from collaborations in the past and we have used QPatch with great success, so it was an obvious choice to start up the partnership again to meet the increased demand. Of course, our clients demand high-quality data, and many have specific requests such as running assays in physiological solutions and better temperature control during runs. QPatch ll was the obvious choice for us since it meets all these demands and more. QPatch II has some great updates and new features, and the new design is stunning. Most significantly, it’s great to be part of the Sophion family again and I look forward to future collaborations with them.”
ApconiX are experts in ion channel biology, target safety assessments and in all aspects of nonclinical programme design and delivery.
ApconiX was formed by three AstraZeneca colleagues with the drive and ambition to create a world-renowned company founded on the skills and experience of a growing team with a wide range of expertise in nonclinical drug safety.
The model for the pharmaceutical industry has evolved in recent years with large pharma reducing internal capability and outsourcing key skills to trusted partners. There are many more SMEs and academic groups who also need access to specialised services. https://www.apconix.com/
First ever QPatch ll installation in South Korea
Sophion and SureMedical have successfully installed the first QPatch ll at SK Biopharma in South Korea. SureMedical worked closely with the new user to find the right APC solution for their needs and we are happy to say they decided on a QPatch ll system with temperature control. This solution is a perfect fit for them regarding throughput, obtaining true Giga-ohm seals in physiological solutions and being able to control the temperature accurately at the measurement sites.
Despite these Covid-19 times, installation and training went according to plan and the new users are up and running. We are sure that SK Biopharma will put their new QPatch ll to good use and continue to break new ground in drug discovery.
Virtual User Meeting hosted by Sophion NA
We had a fantastic slate of speakers representing a variety of different industries each presenting their experiences with automated patch clamping. These presentations were followed by a live demo of the QPatch II 48 Automated Patch-Clamp Instrument with a focus on the Temperature Control features. A big thank you to Application Scientist Melanie Schupp and Product Manager Mads Korsgaard for staying late in Ballerup in order to run the demo.
The meeting was well attended with over 50 external participants representing 27 separate institutions. We were thrilled to see attendees from all over the globe, with many calling in from Europe and even Japan.
Thanks also go to all of our speakers who did a fantastic job presenting their research in an engaging way in this new virtual environment, Daniel who did an excellent job of running the program, Schuyler who set up the WebEx platform and managed the production, and Daniel, Sung, and Weifeng for recruiting such a good group of speakers both from the industry as well as academia.
The one thing we will need to work on for our next virtual User Meeting is to figure out how we can get the participants a round of Lord Hobo beer for the annual User Meeting beer tasting event!
If you take a picture of the QR code below you will have the opportunity to open it and see the agenda and the speaker bios.
User Meeting (virtual) – hosted by Sophion NA
The event will be from 11:00 am to 3:30 pm on the 22nd of September, 2020.
The agenda will be as follows:
11:00: Sophion Latest News – Mads Korsgaard, Global Product Manager, Sophion Bioscience
11:30: Jonathan Mann, Group Leader Biology Discovery, Charles River Laboratories
12:00: Alexander Komarov, Senior Research Investigator, Knopp Biosciences
12:30: Dang Dao, Research Director, Astellas Institute of Regenerative Medicine
01:00: Mark Estacion, Research Scientist, Yale University
01:30: Sam Goodchild, Senior Research Scientist, Xenon Pharmaceuticals
02:00: Jim Ellis, Chief Scientific Officer, Nocion Therapeutics
02:30: QPatch II with Temperature Control Demonstration – Sung Hoon Park, Application Scientist, Sophion Bioscience
The titles of the presentations will be announced shortly.
The meeting will be held as a webinar and if you want to join, please send an email to Schuyler King.
We are looking forward to having a successful virtual user meeting.
From teenager to early adulthood
On 5th July 2000, Sophion Bioscience was founded as a spin-off from the Danish pharmaceutical company NeuroSearch. It is hard to believe that 20 years have passed.
From the annals on our servers and a carefully written diary by Sophion’s first CEO Torsten Freltoft, it is fascinating to follow the first years after the founding. As with all start-ups chasing capital was a part of everyday life to secure the development of what ended up being QPatch. Also, longer entries about Fussball-tournaments and fun nights out at conferences take up a lot of space and of course the inauguration of the new facilities that were opened in 2001.
With the launch of the QPatch in 2005, Sophion started manufacturing, and focus changed from securing capital for development to securing global growth. Around that time someone wrote in one of those vision statements, that were very popular in the ’00s, that potential users of the APC systems not only needed the system and measurement plates but that strong support from application scientists and field service engineers was needed by users and lacking from other vendors. Today, 16 years later we operate from the same principles, ensuring that our users are always supported by a dedicated team of Application Scientists and Field Service Engineers.
In the years from 2005-2010 new installs were booming and Sophion was on the list of fastest-growing companies in Denmark for four consecutive years. While production was busy ensuring supply for new users, R&D continued new developments on the QPatch introducing, among others, the worlds-first automated Rs compensation, ligand applications, QPatch HT (48), multi-hole QPlates and current clamp. All features that are now standard on all Sophion products and most commercially available platforms.
In 2011 a major transformation occurred when Sophion was integrated with Biolin Scientific. Although ‘only’ 11 years old at that point it forced Sophion to grow-up quickly as a company and we still benefit today from the professionalism and structure that was introduced in the Biolin years. A more efficient supply chain and financial reporting system, as well as our ISO 9001 certification, are all processes that we enjoy today and that made us better equipped for the future.
When Qube 384 was introduced in 2014 it changed the way ion channel drug discovery could be done. With 384 individual channels, patch-clamp experiments running primary screening could suddenly be performed. With the introduction of the stacker solution in 2015, it became possible to perform overnight unattended screens of up to 15 QChips, something which is performed routinely by leading CROs and pharma companies on Qube 384 today.
However, the integration into a larger corporation was not a commercial success, and in 2017 a management buyout resulted in Sophion again being “masters in our own house”. After that, things have speeded up again, as many of our current and new partners have noticed. With the introduction of QPatch II 48, QPatch II 16, Qube Opto, online V½ estimation, and the new improved temperature controller, our APC systems are now easier than ever to use, with more advanced features. Double-digit growth, year on year, for the past 4 years has put us in an interesting new situation where we are running more EU projects, more industry partnerships, and more academic collaborations than ever.
In 2020 Sophion Bioscience is stronger than ever, and despite a challenging “Corona-quarter” in Q2-2020”, the future looks bright and promising. While parts of the world are still in lockdown, the crates shipped from Copenhagen in the past few weeks are a sure sign that other parts of the world are opening up again.
With Qube and QPatch installs in all major pharmaceutical companies we are proud to have left our mark on the ion channel field for the past 20 years and plan to continue doing just that for the next 20 years as well.
“Good habits formed at youth make all the difference”
We do not know what the future holds. In the first twenty years, we have managed not only to bring the world’s best APC platforms to market, combining high performance and data quality with a design that makes them so easy to use that patch clamping is accessible to everybody. We promised back then to “take the voodoo out of patch clamping”, and we believe we have achieved just that.
What we can promise you for the future; We will continue to be inquisitive and innovative. We will continue to push the boundaries, enabling ion channel drug discovery and adjacent fields by combining ease-of-use with performance. We will do that while honouring the vision from 2004 because we ‘choose to focus on customer support’.
First CiPA Paper is published in Nature Scientific Reports
We are happy to see results from the first large CIPA study that has been published in Nature Scientific Reports. The study was co-authored by Sophions own Anders Lindqvist, but lots of credit should also go to the rest of the team.
- Kramer et Al. (2020) “Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells”, Nature Scientific Reports volume 10, Article number: 5627
Results from this large multi-site study provide estimates of the variability associated with IC50 values characterizing the blocking potency of 12 drugs on 4 prominent human cardiac currents using suggested experimental protocols across five automated patch platforms and 17 sites.
QPatch results were provided by ourselves and three independent QPatch users (4 in all) and while platforms are anonymized in the paper we can still say that results confirmed what we already knew.
For the record QPatch data was only run at room temperature. With the newly launched temperature control module for QPatch II that enables accurate control of temperature within a range from 10-42°C with a precision of ±0.5°C, we look forward to running more cardiac assays at elevated temperatures. Read more about the QPatch II temperature control solution here.
Also, the original instructions from the Food and Drug Administration (FDA) did not recommend the use of fluoride in the solutions. For most assays on Sophion ‘Qube 384’ we use fluoride to increase the seal resistance, and since it was not recommended, Qube was omitted from this study. We have now learned that others have used fluoride/seal enhancers during this study and agreed with FDA to include Qube in future CiPA studies. We look forward to that since many laboratories already are using Qube for cardiac liability testing.
For questions please contact Sr. Application Scientist Anders Lindqvist
8 hours unattended hERG screening with >97% success rates
With Qube 384 fitted with stacker and temperature control and with a good hERG cell line, you can perform unattended experiments for more than 8 hours with a single click on “run”. Quality control is applied automatically and results in not less than a minimum of 97% of successful experiments from each plate with an average Z’ value of 0.76 demonstrating a very large screening window.
During prolonged unattended runs the Qube stacker will feed QChips and compound plates, while the temperature control ensures a stable temperature around the cells (in this case 25 °C).
Want to know more? Read the full report here.
Sophion User Meeting, Copenhagen 2019
We look forward to seeing you for the annual European Sophion User Meeting. This year the meeting will be held at our premises in Copenhagen, and we are preparing a two-day event with a full-day scientific programme on day 1 and a hands-on workshop on day two, where you can get the chance to discuss with our ion channel experts.
We plan to start around 9.00 AM on Thursday, September 5th and wrap up just after lunch on Friday, September 6th giving you the chance to spend the weekend in wonderful Copenhagen.
The user meeting is kindly sponsored by:
5th September 2019
09.00 Registration – tea/coffee
09.15 Welcome remarks
Thais Johansen, Sophion Bioscience A/S
09.30 P2X3 and P2X2/3: The hare and the tortoise….
Jean Francois Rolland, Axxam SpA
10.00 Strategies for reducing attrition in early drug discovery
David Downie, GSK
11.00 NDMA assays on the Qube system
Abigail Marklew, Charles River Labs
11.30 QPatch HTX assay development for TRPM5 channel to successfully identify potentiators and blockers
Caterina Virginio, Aptuit (Evotec)
12.00 Potency determination of positive Nav1.1 modulators measured on QPatch II
Julie Klint, Lundbeck
13.30 TMEM16A potentiation: a novel therapeutic approach for the treatment of cystic fibrosis
Sarah Lilley, Enterprise Therapeutics
14.00 Resin-acid derivatives as hKv7.2/7.3 channel openers
Nina Ottosson, Lindköping University
14.30 Recent drug discovery applications run on QPatch in CRO collaborative mode
Edward Humphries, Metrion Biosciences
15.30 Update on QPatch II
Göran Mattsson, Sophion Bioscience A/S
15.50 Update on Qube; adaptive protocols and more…..
Mads P G Korsgaard, Sophion Bioscience A/S
16.10 Sophion developments projects update
Sandra Wilson, Sophion Bioscience A/S
16.30 Wrap up
17.00 Transport to the evening event
18.00 Dinner at Færgen Ellen / Kontiki Bar
6th September 2019
09.30 Workshop day is a day dedicated the user where we will touch base with the below issues:
- Adaptive voltage protocols NEW FEATURE!
- Temperature control, new feature on QPatch II coming up!
- Custommade protocols
- Advanced analysis – bring your own assays
- Tips and tricks for cultivating cells
- Learn about the daily cleaning procedure of your APC system
If you have other issues you’d like to hear about please let us know. Drop us an email.
Mechanism of action elucidated with Qube
Two papers were recently published mechanistic studies; in Inhibitory effects of cannabidiol on voltage-dependent sodium currents Xenon together with Simon Frasier University used temperature control on Qube to describe the potency and mechanism of cannabidiol binding to voltage-gated sodium channels. Interestingly the potency is higher at lower temperatures. In Selective Nav1.7 Antagonists with Long Residence Xenon together with Genentech describe the mechanism of several of their compounds in selectively inhibiting Nav1.7, which is relevant in relation to inflammatory and neuropathic pain. These compounds act very slowly, but Qube allows more than one hour long experiments with very good voltage control during the whole experiment or as the authors state:
“Appropriate filters for minimum seal resistance and minimum current size were applied, and series resistance was compensated >80% to yield high- quality sodium channel recordings on par with manual voltage clamp techniques”
Qube Opto 384 – for optical stimulation of ion channels or compounds.
Optical stimulation combined with Automated Patch Clamp allows for precise control of e.g. channelrhodopsins, caged compounds and pacing studies. To allow for even better control than with our standard APC solutions, we have now integrated 384 adjustable LEDs to allow for optical stimulation of ion channels, ligands or compounds.
To compensate for heating due to the large amount of energy released, we have adapted our on-site temperature control, so temperature effects are reduced to a minimum.
To avoid desensitization from ambient light we have darkened the cabinet so Qube looks even cooler, having a distant resemblance to a well-known character from a movie happening in a galaxy far, far away.
- 384 LEDs to ensure consistent and even light distribution throughout all 384 sites
- Light ramps and other waveforms through adjustment of timing, duration and intensity of light
- Integrated temperature control to avoid unwanted temperature effect
- Full LED control integrated in Qube software
- Dark cabinet allows for automated handling of light sensitive compounds and cells
During the coming months we will be playing with this new setup ourselves together with a few select partners. If you are also interested to discover the full potential of this setup and would like to come play with us, you are welcome to contact Sandra Wilson (firstname.lastname@example.org) or visit booth #518 at Biophysics for more information.
Safety Pharmacology Society annual meeting
Hope to see you at the annual Safety Pharmacology Meeting 2017 in Berlin. Meet us at booth #113 and speak with our ion channel experts on site.
When: 24th to 27th September
Venue: Maritim Hotel Berlin
Poster presentation (Poster #022)
Temperature effect on hERG channel pharmacology measured by using the Qube automated patch clamp system.
The human ether-à-go-go related gene (hERG) function is important for cardiac repolarization and inhibition of the channel can prolong the cardiac action potential, which give increased risk for ventricular arrhythmias including torsade des points (TdP). Therefore, In vitro evaluations of the compound effects is performed on the hERG channel routinely in drug development projects to detect potential arrhythmic side-effects.
Usually these compound measurements are carried out at ambient temperatures. Previously it has been shown that the potency for many compounds have been underestimated when compared to near physiological temperature tests. Therefore, a temperature controlled measuring environment is beneficial when testing compounds for the aims as mentioned here.
Until recently, the only possibility to test compound potency under voltage control conditions has been the manual patch clamp technique. Now automated patch clamp instruments with temperature control have come available making it possible to perform up to 384 parallel recordings at controlled temperatures ranging from 18°C and above.
Here we used an automated patch clamp system, Qube, to study the effect of temperature on concentration response relationships on a panel of compounds known to block the hERG channel. Qube has a temperature controlled test environment and in these studies, we show that temperature merits being taken into consideration when evaluating for hERG potency.
hERG compound screening at 22°C and 35°C on QPatch II
In this study, by using our QPatch II system and the temperature control feature, we report a significant difference in hERG kinetics at 22°C and 35°C. By testing four hERG blockers, we were able to
Qube and QPatch posters presented at SPS 2018
A total of six posters with results from Qube and QPatch were presented at the SPS annual meeting in Washington DC covering cardiac safety channels:
- Pfizer (Donglin et al): Simultaneous Measurement of Cardiac NaV1.5 Peak and Late Currents in an Automated QPatch Platform
- Pfizer (Donglin et al): Simultaneous Measurement of Cardiac hERG and NaV1.5 Currents Using an Automated Qube® Patch Clamp Platform
- Metrion Biosciences (Humphries et al): New CiPA cardiac ion channel cell lines and assays for in vitro proarrhythmia risk assessment
- Eurofins (Koci et al): Optimization of Cardiac CiPA Targets (hCaV1.2 and hKCNQ1/hminK) on the QPatch HT Automated System
- Eurofins (Renganathan et al): Automated High Throughput Na+ Late Current Assay on QPatch HT Platform for CiPA28
- Sophion Bioscience (Lindqvist et al): Estimating hERG drug binding using temperature-controlled high throughput automated patch clamp
31 new Publications and Reports from Q3
We have been informed that we missed a few publications from the Q3 list we posted some weeks ago. Thanks for letting us know…thats what friends are for.
Here is the (hopefully) complete list of publications from Q3 (and a part of Q2).
Learn more about how cannabis inhibits Nav currents at therapeutically relevant concentrations or venom from the giant red bull ant published by, among others, Xenon Pharmaceuticals, GSK, AstraZeneca, Sanofi, Eisai, Uni Queensland and more
Peer reviewed publications
- Sokolov et Al 2018. Co-expression of β Subunits with the Voltage-Gated Sodium Channel NaV1.7: the Importance of Subunit Association and Phosphorylation and Their Effects on Channel Pharmacology and Biophysics. Journal of Molecular Neuroscience (LINK)
- Kanase et Al 2018. 4-Substituted carbamazepine derivatives: Conformational analysis and sodium channel-blocking properties. Bioorganic & Medicinal Chemistry, Volume 26, Issue 9 (LINK)
- Gonçalves et Al. 2018. Direct evidence for high affinity blockade of NaV1.6 channel subtype by huwentoxin-IV spider peptide, using multiscale functional approaches. Neuropharmacology, Volume 133, 404-414 (LINK)
- Zha et Al. 2018. Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy. European Journal of Medicinal Chemistry, Volume 148, Pages 140-153 (LINK)
- Israel et Al. 2018. The E15R Point Mutation in Scorpion Toxin Cn2 Uncouples Its Depressant and Excitatory Activities on Human NaV1.6. J. Med. Chem., 2018, 61 (4), pp 1730–1736 (LINK)
- Loucif et Al. 2018. GI‐530159, a novel, selective, mechanosensitive two‐pore‐domain potassium (K2P) channel opener, reduces rat dorsal root ganglion neuron excitability. British Journal of Pharmacology (LINK)
- Xu et Al. 2018. Synthesis and biological evaluation of a series of multi-target N-substituted cyclic imide derivatives with potential antipsychotic effect. European Journal of Medicinal Chemistry, Volume 145, Pages 74-85 (LINK)
- Agwa et Al 2018. Efficient Enzymatic Ligation of Inhibitor Cystine Knot Spider Venom Peptides: Using Sortase A To Form Double-Knottins That Probe Voltage-Gated Sodium Channel NaV7. Bioconjug Chem. 2018 Sep 12. (LINK)
- Colley et Al 2018. Screening strategies for the discovery of ion channel monoclonal antibodies. Current Protocols in Pharmacology, 82, e44. (LINK)
- Robinson et Al 2018. A comprehensive portrait of the venom of the giant red bull ant, Myrmecia gulosa, reveals a hyperdiverse hymenopteran toxin gene family. Science Advances 12 Sep 2018:Vol. 4, no. 9 (LINK)
- Procopiou et Al 2018. Discovery of (S)-3-(3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic αvβ6 Integrin Inhibitor for the Inhaled Treatment of Idiopathic Pulmonary Fibrosis. Med. Chem (LINK)
- Ghovanloo et Al 2018. Inhibitory effects of cannabidiol on voltage-dependent sodium currents. Journal of Biological Chemistry (LINK)
- Bankar et Al 2018. Selective Nav1.7 Antagonists with Long Residence Time Show Improved Efficacy against Inflammatory and Neuropathic Pain. (LINK)
- Bettini et Al 2018. NMDA Receptor Modulators in QPatch. Evotech Gmbh (LINK)
- Boddum et Al 2018. Optical modulation of ion channels. Sophion Bioscience. (LINK)
- Boddum et Al 2018. GABAA receptor pharmacology evaluted in overexpressing HEK cells and primary astrocytes on QPatch. Sophion Bioscience. (LINK)
- Standing et Al 2018. Development of high-throughput electrophysiological assay for the screening of hERG ion channel modulators using Sophion Qube 384. GlaxoSmithKline (LINK)
- Klint et Al 2018. HT Automation for patch clamp based primary screen for Nav1.1 using Qube 384. Lundbeck A/S (LINK).
- Bouyer and Hebeisen 2018. NaV5 big late : An inactivation deficient mutant of NaV1.5 as screening tool for late sodium currents of the cardiac action potential. B’SYS (LINK)
- Douglin Guo et Al. 2018 Simultaneous measurement of cardiac Nav5 peak and late current in an automated QPatch platform. Pfizer. SPS 2018
- Koci et Al 2018. Optimization of Cardiac CiPA targets (Cav2 and KCNQ1/MinK) on the QPatch HT automated system. Eurofins. SPS 2018
- Huphries et Al 2018. New CiPA ion channel cell lines and assays for in vitro proarythmia risk assessment. Metrion Biosciences. SPS 2018. (Will be uploaded soon)
- Donglin Guo et Al 2018. Simultaneous measurement of cardiac hERG and Nav5 currents using an automated Qube patch clamp platform. Pfizer. SPS 2018. (Will be uploaded soon)
- Renganathan et Al 2018. Automated High Throughput Na+ Late current Assay on QPatch HT platform for CiPA28. Eurofins. SPS 2018 (Will be uploaded soon)
- Lindqvist and Christensen 2018. Estimating hERGdrug binding using temperature-controlled high throughput automated patch clamp. Sophion Bioscience. SPS 2018 (Will be uploaded soon)
- Humphries and Binzer 2018. CiPA hERG Milnes kinetic assay on Qpatch (LINK)
- Sauter D 2018. Voltage and current clamp recordings of Cor.4U® human iPS cell-derived cardiomyocytes using Sophion’s QPatch (LINK)
- Boddum K 2018. Ligand gated ion channels: GABAA receptor pharmacology on QPatch (LINK)
- Sauter D 2018. Human iPS cell-derived cardiomyocytes (Cor.4U®) on Sophion’s Qube 384: voltage and current clamp recordings (LINK)
- Rosholm & Schupp 2018.2 recordings using QPatch (LINK)
- Schupp 2018. 8 hours unattended hERG run with ≥97% success rate and consistent pharmacology results (LINK)
QPatchA barcode scanner on the gripper armand stacking of plates on the workplane provides faster and more
8 hours unattended hERG run with ≥97% success rate and consistent pharmacology results
The cardiac ion channel encoded by KCNH2, also known as the human ether-à-go-go-related gene (hERG) or KV11.1 can lead to cardiac arrhythmia when blocked and is thus a major off-target in drug discov
Development of Automated Patch Clamp Technique to Investigate CFTR Chloride Channel Function
The chloride (Cl–) channel cystic fibrosis transmembrane conductance regulator (CFTR) is defective in cystic fibrosis (CF), and mutation of its encoding gene leads to various defects such as ret
QChip 384 – Multi HoleThe 10-hole QChip is meant for high throughput screening with high success rates: Giga-seal technol
Our technologiesRead more about the different technologies that apply to automated patch clamp: • Biochips and P
Qube 384High throughput screening made easy Qube 384, Sophion’s high throughput screening system, is our